Marc Iskowitz

Most recent articles by Marc Iskowitz

Lumanity’s shopping spree continues with research firm
Lumanity’s shopping spree continues with research firm
Marc Iskowitz
June 15, 2022
10:58 am

Endpoint Outcomes, a patient-centered research outfit, becomes Lumanity’s seventh acquisition since 2020.

Amylyx’s ALS drug would not be cost-effective if priced like another ALS drug on the market
Amylyx’s ALS drug would not be cost-effective if priced like another ALS drug on the market
Marc Iskowitz
June 14, 2022
2:42 pm

The pricing watchdog ICER believes policymakers should debate short-term pricing options until the drug’s benefits can be ascertained.

Bluebird’s adcomm sweep sets stage for gene-therapy launches
Bluebird’s adcomm sweep sets stage for gene-therapy launches
Marc Iskowitz
June 13, 2022
2:39 pm

Bluebird’s wins were followed by news over the weekend that patients with inherited blood disease saw prolonged benefit from gene-edited therapy.

Lumicell beefs up its commercial team
Lumicell beefs up its commercial team
Marc Iskowitz
June 13, 2022
1:00 pm

The firm hired a pair of med-tech vets, bolstering its team with a new chief commercial officer and VP of marketing.

3 practice-changing data readouts from ASCO
3 practice-changing data readouts from ASCO
Marc Iskowitz
June 10, 2022
10:30 am

These readouts have clinicians and analysts alike talking about a shakeup in cancer care.

BlueBird Bio’s 2-day reckoning is at hand
BlueBird Bio’s 2-day reckoning is at hand
Marc Iskowitz
June 9, 2022
9:36 am

Briefing documents suggest that one of two potential gene therapy launches may be in for a rough ride.

PhRMA’s 7-figure ad buy targets drug middlemen
PhRMA’s 7-figure ad buy targets drug middlemen
Marc Iskowitz
June 8, 2022
2:31 pm

The campaign launched as the FTC greenlighted a probe into the supposedly anti-competitive practices of the largest PBMs.

Amarin trims Vascepa sales staff by 65% as generic entrants bite into revenue
Amarin trims Vascepa sales staff by 65% as generic entrants bite into revenue
Marc Iskowitz
June 7, 2022
3:04 pm

The impact of three generic rivals on its fish-oil derived heart pill prompted the latest cost-cutting move.

Fishawack buys DC policy and market access shop Avalere
Fishawack buys DC policy and market access shop Avalere
Marc Iskowitz
June 7, 2022
2:57 pm

The deal follows the acquisition of HEOR consultancy Policy Analysis earlier this year.

The plot thickens: A100 sees double-digit growth despite tricky terrain
The plot thickens: A100 sees double-digit growth despite tricky terrain
Marc Iskowitz
June 7, 2022
5:00 am

Year 2 of the pandemic brought more unpredictability, but record revenue shows the industry thrived amid the upheaval.

  • From Our Partners